Register Now - Unlocking Longitudinal Patient-Reported Outcomes: The Untapped Value of Specialty Pharmacyocking
|Articles|July 25, 2013

PSI Expands International Clinical Trial Presence to South Africa

Today, PSI CRO, a full-service contract research organization, announced their expansion into South Africa.

South Africa is a multi-cultural nation with a population of ~50 million people.  It has a long history of conducting clinical trials.  As such, there exists a strong infrastructure to support all needed activities including regulatory oversight and experienced researchers.  Data generated from South African trials receives international acceptance. Expert opinion leaders work in South Africa, providing a high standard of medical care.  Therefore, patients who have received state-of-the-art therapy, in addition to treatment-naïve patients, may be recruited for clinical trials.  PSI will expand its access to all African countries from the strong base in Pretoria. PSI’s current experience in South Africa stretches across the areas of oncology, CNS, urology, diabetes and other therapeutic areas.


Related to this article

Where AI Leads in Trial Design—and Where Humans Still Need To
In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.